Tempramed signs distribution agreement with Guri

Executive Summary

• Tempramed Technologies signed an exclusive commercial distribution agreement with Guri A.A.O., a leading Israeli distributor, to market its full product line across Israel's retail market, marking a strategic pivot from direct-to-consumer to large-scale retail and B2B channels.
• The company filed its interim financial statements for the three and nine months ended September 30, 2025, including management’s discussion and analysis.
• Tempramed provided an update on its previously announced non-brokered private placement, confirming it is advancing toward closing subject to customary conditions and regulatory approvals.

Key Details

• Distribution Agreement:
  • Partner: Guri A.A.O., one of the top five distributors in Israel's retail sector with over 50 years of industry leadership.
  • Scope: Exclusive rights to market and sell Tempramed's full product line, including the VIVI line and upcoming temperature-sensitive medical storage products.
  • Market Access: Guri has relationships with 2,500 of Israel's largest supermarkets, pharmacy chains, HMOs, and independent pharmacies.
  • Strategic Impact: Marks a pivot from a direct-to-consumer online model to pharmacy-led distribution and B2B medical payers, aiming to reduce patient acquisition costs and integrate solutions into standard-of-care.
• Financial Filings:
  • Filed interim financial statements for the three and nine months ended September 30, 2025.
  • Filed management’s discussion and analysis (MD&A) for the same periods.
  • Results available on SEDAR+.
• Financing Update:
  • Update on the non-brokered private placement previously announced on October 21, 2025.
  • Company confirms it is working toward closing the offering.
  • Closing is subject to customary conditions and regulatory approvals.
  • The offering remains a priority to support strategic initiatives, including the Guri partnership and transition to pharmacy-led channels.
• Product & Market Context:
  • Products include patented, FDA-registered thermal insulation devices (VIVI Cap, VIVI Epi) that operate without external power.
  • Target markets include health systems and payors requiring cold-chain solutions for injectables, biologics, fertility medications, GLP-1 therapies, and insulin.
  • Company holds eight patents and regulatory approvals across major jurisdictions.

Notable Quotes

• Oded Guri, Owner and CEO of Guri: "Tempramed is an innovative, cutting-edge and revolutionary company that is transforming how temperature sensitive medication is stored... Retail executives have already expressed a strong willingness to start selling the products. I'm proud to be among the first distributors of Tempramed products in the global market..."
• Ron Nagar, CEO of Tempramed: "As we expand globally, our focus is on embedding Tempramed's technology within the retail and clinical ecosystems where patients already receive care... This is a major step in making temperature-safe medication storage the global standard, improving outcomes, reducing wastage and enhancing safety for patients who rely on temperature-sensitive therapies every single day."